See every side of every news story
Published loading...Updated

Capricor announces that individuals with Duchenne treated with deramiocel had significantly less progression in loss of upper limb function

Summary by CureDuchenne
Capricor Therapeutics received early funding from CureDuchenne, and today Capricor released new data reporting that individuals treated with deramiocel over three years experienced an average decline in Performance of the Upper Limb (PUL 2.0) total score of 3.46 points, compared to a 7.19-point decline in the external comparator group (p=0.019). Capricor reports that this equates to a 52% slowing of disease progression.  Capricor’s Biologics Lic…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Gacetín Madrid broke the news in on Sunday, March 16, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.